General
Preferred name
SECNIDAZOLE
Synonyms
RP-14539 ()
PM-185184 ()
1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol ()
PM 185184, RP 14539 ()
Secnidazole ()
Secnidal ()
Flagentyl ()
Secnidazole anhydrous ()
Solosec ()
Secnidazol ()
Ornidazole metabolite m4 ()
Deprozol ()
SYM-1219 ()
Sabima ()
NSC-759812 ()
Secnol ()
RP 14539 ()
P&D ID
PD000955
CAS
3366-95-8
Tags
available
drug
Approved by
FDA
First approval
2017
Drug indication
Amoebiasis
Bacterial vaginosis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Secnidazole (RP-14539) is an orally active azole antibiotic and a imidazole mitigator of Serratia marcescens virulence. Secnidazole, as an analog of acylhomoserine lactones, effectively inhibits QS resulting in the attenuation of Pseudomonas aeruginosa pathogenesis. Secnidazole has antimicrobial activity against many anaerobic Gram-negative and Gram-positive bacterial species in vitro. Secnidazole can be used for the research of various diseases, such as amoebiasis and giardiasis, and bacterial vaginitis[1][2][3].
PRICE
29
DESCRIPTION
Secnidazole is a broad-spectrum nitroimidazole antimicrobial compound that exhibits antiprotozoal and antibacterial (Gram-positive and Gram-negative) activities.
(GtoPdb)
DESCRIPTION
Secnidazole is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including Metronidazole and Tinidazole. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. It is indicated for the treatment of bacterial vaginosis in adult women.
(Enamine Bioactive Compounds)
DESCRIPTION
Secnidazole (PM-185184) is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
3
Compound Sets
23
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
185.08
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
0.48
TPSA
81.19
Fraction CSP3
0.57
Chiral centers
1.0
Largest ring
5.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Parasite
Bacterial
MOA
Antibiotic
Pathway
Microbiology/virology
Anti-infection
Source data
